Compare Immunovant Inc. Common Stock (IMVT) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Manhattan Associates Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B), while Manhattan Associates Inc trades at $206.18 (market cap $12.06B). The key difference: Manhattan Associates Inc is the larger of the two by market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Manhattan Associates Inc for 12 Days on average.
| IMVT | MANH | |
|---|---|---|
Market Cap | $6.25B | $12.06B |
Volume | 1,755,411 | 376,150 |
Sector | Health | Technology |
52-Week High | $44.96 | $223.76 |
52-Week Low | $17.03 | $120.88 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $5.35B | $11.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Manhattan Associates (MANH) trades at $202.11, down 0.36% with bearish technical signals but strong fundamentals. The stock shows robust profitability with 18.67% net margins and consistent earnings beats, though valuation multiples appear elevated. Recent news includes a law firm investigation into fiduciary duties and a downgrade to neutral by DA Davidson, while the company launched new solution editions to expand market reach.
The outlook balances strong operational performance against high valuation and legal scrutiny. Upside potential exists from continued earnings momentum and product innovation, but risks include the ongoing investigation and competitive pressures. Analyst consensus remains bullish with a $210.50 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
